Navigation Links
Volcano Reports 18 Percent Increase in Total Third Quarter Revenues

SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today that revenues for the third quarter of 2011 increased 18 percent versus the third quarter of 2010.

For the quarter ended September 30, 2011, Volcano reported revenues of $85.8 million versus revenues of $72.9 million in the third quarter a year ago. Year-over-year medical segment revenues increased 24 percent in the third quarter of 2011. Industrial segment revenues in the third quarter declined 54 percent versus a year ago, due to reduced spending in the telecommunications sector.

The company reported net income on a GAAP basis of $2.6 million, or $0.05 per diluted share, in the third quarter of 2011, versus net income of $5.6 million, or $0.10 per diluted share, in the third quarter of 2010.

For the first nine months of 2011, Volcano reported revenues of $250.8 million, an 18 percent increase over revenues of $212.9 million in the same period a year ago. The company reported GAAP net income of $8.7 million, or $0.16 per diluted share, in the first nine months of 2011. This compares with GAAP net income of $7.0 million, or $0.13 per diluted share, in the same period in 2010.

"Volcano's medical segment business experienced solid growth in the third quarter, driven by a 48 percent increase in FFR (Fractional Flow Reserve) disposable revenues, as FFR continued its higher market penetration and we continued to gain market share for both our FFR and IVUS (Intravascular Ultrasound) businesses in key geographies. These gains occurred despite a challenging macro-economic environment that is impacting procedure activity, particularly for our IVUS business," said Scott Huennekens, president and chief executive officer.

"Given the increased focus on comparative effectiveness, we continue to be optimistic about the long-term prospects for our current and future offerings—particularly IVUS—as  recent data from the Matrix study reinforces positive outcomes with respect to reduction in deaths and adverse events when using IVUS versus the use of angiography alone," he added.

Huennekens said the company continues to advance its long-term growth strategy. "We are making investments in product development and clinical programs to further our vision as the leading therapy guidance company with a platform that delivers precision guided therapy and diagnosis utilizing intravascular imaging, physiology and future technologies. Over the next year, we will be introducing enhancements to our current offerings, as well as new products that will enable us to address new markets," he noted.

Guidance for 2011

The company said that given current expectations for healthcare procedure activity and telecom business sales, it is narrowing the top range of its revenue guidance for fiscal 2011 from $342-$347 million to $342-$345 million. It continues to expect that gross margin will be 65-66 percent and that operating expenses will be 58-60 percent of revenues. The company expects earnings per diluted share for fiscal 2011 will be $0.19-$0.21. The company said that as a result of its projected ongoing GAAP profitability, it is assessing its ability to release a portion of its deferred tax valuation allowance, which may result in additional estimated net income of approximately $25.0 million, or $0.45 per diluted share, in the fourth quarter of 2011.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (631) 291-4555, passcode 14128534, or via the company's website at Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through November 7, at (404) 537-3406 passcode 14128534, and via the company's website at

About Volcano

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's revenue, expense or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in achieving those projections, the effect of competitive and economic factors, and the company's reaction to those factors, on purchasing decisions with respect to the company's products, the pace and extent of market adoption of the company's products and technologies, the inherent uncertainty in the process of obtaining regulatory approval or clearance for Volcano's products or devices, the success of Volcano's   growth strategies, risks associated with Volcano's international operations, the impact of the recent events in Japan, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent annual report on Form 10-K for the year ended December 31, 2010, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited) September 30, December 31,20112010 Assets Current assets: Cash and cash equivalents

43,429 Short-term available-for-sale investments  

154,314175,283 Accounts receivable, net

63,41359,133 Inventories

46,46340,499 Prepaid expenses and other current assets

8,6736,643 Total current assets

325,954324,987 Long-term available-for-sale investments

33,92826,804 Property and equipment, net

73,41156,503 Intangible assets, net

15,26117,103 Goodwill

2,4872,487 Other non-current assets

431,566 Liabilities and Stockholders' Equity Current liabilities: Accounts payable

3,895 Accrued compensation

15,68718,241 Accrued expenses and other current liabilities

14,10221,960 Deferred revenues

6,4235,898 Current maturities of long-term debt

7256 Total current liabilities

49,00060,050 Long-term debt

94,54391,236 Deferred revenues

2,8782,466 Other

3,2153,478 Total liabilities

149,636157,230 Stockholders' equity

431,566VOLCANO CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(Unaudited)Three Months Ended
September 30,Nine Months Ended
September 30,2011201020112010Revenues





212,910Cost of revenues29,53825,95584,17579,686Gross profit56,22946,931166,623133,224Operating expenses:Selling, general and administrative36,03429,565106,98292,726Research and development13,92810,18540,33729,637Amortization of intangibles8606272,5721,821In-process research and development---65Total operating expenses50,82240,377149,891124,249Operating income5,4076,55416,7328,975Interest income226106701274Interest expense(1,834)(249)(5,895)(267)Exchange rate loss(502)(91)(1,181)(635)Other--(2)(19)Income before provision for income taxes3,2976,32010,3558,328Provision for income taxes6697351,6841,363Net income





6,965Net income per share:Basic










0.13Shares used in calculating net income per share:Basic52,51750,81052,18850,339Diluted54,94753,27854,60553,032VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
September 30,Percentage Change Nine Months Ended
September 30,Percentage Change 201120102010 to 2011201120102010 to 2011Medical segment:Consoles:United States

$  6.0$  5.74

%$  17.6$  17.32



1.51.3136.35.221Rest of world

1.60.81053.83.58Total Consoles

$  9.7$  8.119$  29.4$  27.67IVUS single-procedure disposables:United States


%$  56.2$  51.010



6.24.82717.815.316Rest of world

1.61.2324.83.631Total IVUS single-procedure disposables

$49.8$42.617$147.4$122.121FM single-procedure disposables:United States

$  9.3$  6.346

%$  26.1$  17.648



5.73.75417.011.350Rest of world

0.30.5(30)1.51.315Total FM single-procedure disposables

$16.7$11.348$  47.9$  32.547Other

$  6.84.746

%$  16.612.731

%Sub-total medical segment

$83.0$66.724$241.3$194.924Industrial segment

$  2.86.2(54)$


SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
2. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
3. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Volcano Corporation Announces Litigation Status
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
8. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
9. Volcano Announces Installed Base Growth Milestone
10. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
11. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
Post Your Comments:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):